Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis

Bibliography

• Compston A, Coles A. Multiple sclerosis. Lancet 2002;359:1221-31
   PubMed Web of Science ®Google Scholar
• Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2003; (4):CD001332
   Google Scholar
• Smith CR, LaRocca NG, Giesser BS, High-dose oral baclofen: experience in patients with multiple sclerosis. Neurology 1991;41:1829-31
   PubMed Web of Science ®Google Scholar
• Feldman RG, Yound RR, Koella W. Spasticity: disordered motor control. Symposium synopsis. Year Book Medical; Chicago: 1980. p. 485-94
   Google Scholar
• Nathan P. Some comments on spasticity and rigidity. In: Desmedt JE, editor. New developments an electromyography and clinical neurophysiology. Karger, Basel; 1973
   Google Scholar
• Young RR. Spasticity: a review. Neurology 1994;44(Suppl 9):S12-20
   PubMedGoogle Scholar
• O'Connor AB, Schwid SR, Herrmann DN, Pain associated with multiple sclerosis: systematic review and proposed classification. Pain 2008;137:96-111
   PubMed Web of Science ®Google Scholar
• McCombe PA, Gordon TP, Jackson MW. Bladder dysfunction in multiple sclerosis. Expert Rev Neurother 2009;9:331-40
   PubMed Web of Science ®Google Scholar
• Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess 2003;7:1-111
   Google Scholar
• Klein TW, Newton C, Larsen K, The cannabinoid system and immune modulation. J Leukoc Biol 2003;74:486-96
   PubMed Web of Science ®Google Scholar
• Howlett AC, Barth F, Bonner TI, International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002;54:161-202
   PubMed Web of Science ®Google Scholar
• Croxford JL. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 2003;17:179-202
   PubMed Web of Science ®Google Scholar
• Cabral GA, Raborn ES, Griffin L, CB2 receptors in the brain: role in central immune function. Br J Pharmacol 2008;153:240-51
   PubMed Web of Science ®Google Scholar
• Tanasescu R, Constantinescu CS. Cannabinoids and the immune system: an overview. Immunobiology 2010;215:588-97
   PubMed Web of Science ®Google Scholar
• Howlett AC, Mukhopadhyay S. Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem Phys Lipids 2000;108:53-70
   PubMed Web of Science ®Google Scholar
• Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986;38:151-78
   PubMed Web of Science ®Google Scholar
• Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 2006;66:234-46
   PubMed Web of Science ®Google Scholar
• Malfait AM, Gallily R, Sumariwalla PF, The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proceedings of the National Academy of Sciences of the United States of America 2000;97:9561-6
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Peters M, Murillo-Rodriguez E, Cannabidiol--recent advances. Chemistry & biodiversity 2007;4:1678-92
   PubMed Web of Science ®Google Scholar
• Pertwee RG. Neuropharmacology and therapeutic potential of cannabinoids. Addict Biol 2000;5:37-46
   PubMed Web of Science ®Google Scholar
• Bisogno T, Hanus L, De Petrocellis L, Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001;134:845-52
   PubMed Web of Science ®Google Scholar
• Baker PB, Gough TA, Taylor BJ. The physical and chemical features of Cannabis plants grown in the United Kingdom of Great Britain and Northern Ireland from seeds of known origin--Part II: second generation studies. Bull Narc 1983;35:51-62
   PubMedGoogle Scholar
• London: house of Lords Select Committee on Science and Technology SO. Cannabis: the scientific and medical evidence; 1998; 4 Nov
   Google Scholar
• Lakhan SE, Rowland M. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurol 2009;9:59
   PubMed Web of Science ®Google Scholar
• Chong MS, Wolff K, Wise K, Cannabis use in patients with multiple sclerosis. Mult Scler 2006;12:646-51
   PubMed Web of Science ®Google Scholar
• Consroe P, Musty R, Rein J, The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1997;38:44-8
   PubMed Web of Science ®Google Scholar
• Clark AJ, Ware MA, Yazer E, Patterns of cannabis use among patients with multiple sclerosis. Neurology 2004;62:2098-100
   PubMed Web of Science ®Google Scholar
• Wade DT, Collin C, Stott C, Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 2010;16:707-14
   PubMed Web of Science ®Google Scholar
• Whittle BA, Guy GW, Robson P. Prospects for new cannabis-based prescription medicines. J Cannabis Ther 2001;1:133-52
   Google Scholar
• Novotna A, Mares J, Ratcliffe S, A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011;18:1122-31
   PubMed Web of Science ®Google Scholar
• Rog DJ, Nurmikko TJ, Friede T, Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005;65:812-19
   PubMed Web of Science ®Google Scholar
• Ratcliffe S, Metz L, Ambler Z. Efficacy results of a study of THC: CBD in central neuropathic pain due to multiple sclerosis. Proceeding of the 24th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2008). Montreal
   Google Scholar
• Notcutt W, Langford R, Davies P, A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex(R) (nabiximols). Mult Scler 2012;18:219-28
   PubMed Web of Science ®Google Scholar
• Zajicek JP, Hobart JC, Slade A, MUltiple Sclerosis and Extract of Cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry 2012. [Epub ahead of print]
   Google Scholar
• Zajicek J, Fox P, Sanders H, Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003;362:1517-26
   PubMed Web of Science ®Google Scholar
• Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004;329:253
   PubMed Web of Science ®Google Scholar
• Wissel J, Haydn T, Muller J, Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial. J Neurol 2006;253:1337-41
   PubMed Web of Science ®Google Scholar
• Freeman RM, Adekanmi O, Waterfield MR, The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct 2006;17:636-41
   PubMed Web of Science ®Google Scholar
• de Ridder D, Constantinescu C.S, Fowler C. Randomised controlled study of cannabis-based medicine (Sativex) in patients suffering from multiple sclerosis associated detrusor overactivity. Proceeding of the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2006). Madrid, Spain
   Google Scholar
• Brady CM, DasGupta R, Dalton C, An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 2004;10:425-33
   PubMed Web of Science ®Google Scholar
• Grant JE, Chamberlain SR, Schreiber L, Neuropsychological deficits associated with cannabis use in young adults. Drug Alcohol Depend 2012;121:159-62
   PubMed Web of Science ®Google Scholar
• Morgan CJ, Gardener C, Schafer G, Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol Med 2011;1-10; Epub ahead of print
   Google Scholar
• Wade DT, Makela P, Robson P, Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004;10:434-41
   PubMed Web of Science ®Google Scholar
• Karschner EL, Darwin WD, McMahon RP, Subjective and physiological effects after controlled Sativex and oral THC administration. Clin Pharmacol Ther 2011;89:400-7
   PubMed Web of Science ®Google Scholar
• Robson P. Abuse potential and psychoactive effects of delta-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf 2011;10:675-85
   PubMed Web of Science ®Google Scholar
• Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 2007;29:2068-79
   PubMed Web of Science ®Google Scholar
• Wade DT, Makela PM, House H, Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006;12:639-45
   PubMed Web of Science ®Google Scholar
• Constantinescu C, Hoggart B, Serpell M, 441 Long Term Open Label Treatment With Sativex® In Patients With Multiple Sclerosis And Neuropathic Pain. Eur J Pain 2006;10:S117c-S8
   Google Scholar
• Collin C, Davies P, Mutiboko IK, Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007;14:290-6
   PubMed Web of Science ®Google Scholar
• Oreja-Guevara C. Clinical efficacy and effectiveness of Sativex((R)), a combined cannabinoid medicine, in multiple sclerosis-related spasticity. Expert Rev Neurother 2012;12(Suppl):3-8
   PubMedGoogle Scholar
• Randall T, Schapiro, Diana M, Spasticity, Balance, Tremor, and Weakness: Factors in Mobility Impairment. In: van den Noort S, Holland NJ, editors, Multiple sclerosis in clinical practice. Demos Medical Publishing, New York; 1999. p. 41-56
   Google Scholar
• Baker D, Pryce G, Croxford JL, Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2001;15:300-2
   PubMed Web of Science ®Google Scholar
• Kubajewska I, Constantinescu CS. Cannabinoids and experimental models of multiple sclerosis. Immunobiology 2010;215:647-57
   PubMed Web of Science ®Google Scholar
• Collin C, Ehler E, Waberzinek G, A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 2010;32:451-9
   PubMed Web of Science ®Google Scholar
• Vaney C, Heinzel-Gutenbrunner M, Jobin P, Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 2004;10:417-24
   PubMed Web of Science ®Google Scholar
• Notcutt W, Price M, Miller R, Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia 2004;59:440-52
   PubMed Web of Science ®Google Scholar
• Wade DT, Robson P, House H, A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003;17:21-9
   PubMed Web of Science ®Google Scholar